Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...

Senores Pharmaceuticals rose 2.16% to Rs 687.75 after its US arm signed a deal to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA, targeting a market size of up to $120 million.

The global opioid market size was US$ 4.5 billion in 2021. The global opioids market is projected to grow to US$ 5.9 billion by 2030 by growing at a compound annual growth rate (CAGR) of 4.2% during ...

Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

The FDA has approved Ajovy for migraine prevention in children and teens, marking the first time a medication in its class is cleared for pediatric use.

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

A new market analysis report reveals the global generic injectable market is poised for explosive growth, with its value ...

Calling to stop using toxic and carcinogenic materials in kindergartens, schools and parks, organizations cite research, note ...

UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics.